Literature DB >> 24529129

Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant.

Kirstin Albers1, Christian Schlein1, Kirsten Wenner2, Peter Lohse3, Alexander Bartelt1, Joerg Heeren1, René Santer2, Martin Merkel4.   

Abstract

Deficiency of apoprotein A-V (apoA-V) can cause hypertriglyceridemia. In an 11 months old boy presenting with a severe hypertriglyceridemia, a formerly unknown 24 nucleotide deletion in exon 2 of the APOA5 gene was detected. The homozygous mutation results in an eight amino acid loss in the signal peptide sequence (c.16_39del; p.Ala6_Ala13del). Screening of control persons proved that this deletion is a rare mutation. Hypertriglyceridemia in the patient was only found at the time when he was breast fed, while after weaning, triglyceride levels were close to normal. Under both dietary conditions, apoA-V protein was undetectable in plasma while post-heparin plasma lipoprotein lipase activity was normal. Expression analysis of normal and mutated protein by Western blot and immunofluorescence in apoA-V deficient primary hepatocytes revealed that, due to changes in the signal peptide, mutated apoA-V was intracellularly missorted to lipid droplets and not secreted. Wild type apoA-V, instead, was not targeted to lipid droplets but transported via endosomal compartments to the plasma membrane for secretion. It is concluded that the c.16_39del mutation in the APOA5 gene leads to hepatic missorting and impaired secretion, which consequently results in undetectable apoA-V plasma levels. The absence of apoA-V in plasma leads under conditions of fat-rich diets to severe chylomicronemia, suggestive for a modulatory role of apoA-V for lipoprotein lipase mediated intravascular triglyceride lipolysis.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  APOA5; ApoA-V; Apolipoprotein A-V; Chylomicronemia; Deletion; Hypertriglyceridemia; Mutation; Signal peptide; Triglyceride

Mesh:

Substances:

Year:  2014        PMID: 24529129     DOI: 10.1016/j.atherosclerosis.2013.12.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.

Authors:  Qin Feng; Susan S Baker; Wensheng Liu; Ricardo A Arbizu; Ghanim Aljomah; Maan Khatib; Colleen A Nugent; Robert D Baker; Trudy M Forte; Yiyang Hu; Lixin Zhu
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

Review 2.  Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact.

Authors:  Montse Guardiola; Josep Ribalta
Journal:  Curr Atheroscler Rep       Date:  2017-07       Impact factor: 5.113

Review 3.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

4.  Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia.

Authors:  Virginia Esteve-Luque; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Emili Corbella; Xavier Corbella; Xavier Pintó; Beatriz Candás-Estébanez
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

Review 5.  Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia.

Authors:  György Paragh; Ákos Németh; Mariann Harangi; Maciej Banach; Péter Fülöp
Journal:  Lipids Health Dis       Date:  2022-02-10       Impact factor: 3.876

6.  Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine.

Authors:  Piao-Piao Huang; Wen-Qiang Zhu; Jing-Mei Xiao; Yi-Qi Zhang; Rong Li; Yang Yang; Li Shen; Fei Luo; Wen Dai; Ping-An Lian; Ya-Xin Tang; Juan-Li Ran; Xian-Sheng Huang
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

7.  Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency.

Authors:  Mikio Takanashi; Takeshi Kimura; Chengcheng Li; Masaki Tanaka; Ako Matsuhashi; Hiroki Yoshida; Akari Noda; Pengfei Xu; Satoru Takase; Sachiko Okazaki; Yoko Iizuka; Hidetoshi Kumagai; Yuichi Ikeda; Takanari Gotoda; Manabu Takahashi; Hiroaki Yagyu; Shun Ishibashi; Toshimasa Yamauchi; Takashi Kadowaki; Guosheng Liang; Hiroaki Okazaki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

Review 8.  Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis.

Authors:  Trudy M Forte; Vineeta Sharma; Robert O Ryan
Journal:  J Biomed Res       Date:  2015-10-20

Review 9.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

Review 10.  Current Diagnosis and Management of Primary Chylomicronemia.

Authors:  Hiroaki Okazaki; Takanari Gotoda; Masatsune Ogura; Shun Ishibashi; Kyoko Inagaki; Hiroyuki Daida; Toshio Hayashi; Mika Hori; Daisaku Masuda; Kota Matsuki; Shinji Yokoyama; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-13       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.